Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension.
Fisher
James P
JP
School of Sport and Exercise Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. j.p.fisher@bham.ac.uk
Fadel
Paul J
PJ
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D017704:Baroreflex / Q000502:physiology; D003714:Denervation; D004599:Electric Stimulation Therapy; D015444:Exercise; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000294:innervation; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors; D013315:Stress, Psychological; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology; D013565:Sympatholytics / Q000627:therapeutic use; D015431:Weight Loss
D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017382:Reactive Oxygen Species; D013565:Sympatholytics; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase